Histologic regression in primary melanomas ?0.75 mm was not associated sentinel node involvement, according to results of a retrospective study.
he findings suggest that sentinel node biopsy in thin melanomas with regression may not be appropriate without additional adverse prognostic factors, the researchers wrote.
A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. This new approach may help develop more effective cancer immunotherapies, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The university researchers teamed up with Cancer Research UK Manchester Institute and King’s College London to discover the way that melanoma skin cancer cells can invade healthy tissue and spread ‘aggressively’ around the body.
Heavily pretreated patients with metastatic melanoma who received the humanized anti-PD-1 monoclonal antibody pidilizumab demonstrated encouraging rates of 12-month OS, according to results of a phase 2 study presented at the ASCO Annual Meeting.
